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Abstract
Background: Benign prostatic hyperplasia is a frequent disease among elderly, and is responsible for considerable
disability. Benign prostatic hyperplasia can be clinically significant due to lower urinary tract symptoms that take
place because the gland is enlarged and obstructs urine flow. Transurethral resection of the prostate remains the
gold standard treatment for patients with moderate or severe symptoms who need active treatment or who either
fail or do not want medical therapy. Moreover, perioperative and postoperative surgery complications as
cardiovascular ones still occur. The incidence of acute myocardial infarction in patients undergoing transurethral
resection of the prostate is controversial. The first studies showed an increase in mortality and relative risk of death
from myocardial infarction in transurethral resection of the prostate group vs open prostatectomy but these results
are in contrast with more recent data.
Discussion: Given the conflicting evidence of the studies in the literature, in this review we are going to discuss
the factors that may influence the risk of myocardial infarction in elderly patients undergoing prostate surgery. We
analyzed the possible common factors that lead to the development of myocardial infarction and benign prostatic
hyperplasia (cardiovascular and metabolic), the stressor factors related to prostatectomy (surgical and
haemodynamic) and the risk factors specific of the elderly population (comorbidity and therapies).
Summary: Although transurethral resection of the prostate is considered at low risk for severe complications, there
are several reports indicating that cardiovascular events in elderly patients undergoing this surgical operation are
more common than in the general population. Several cardio-metabolic, surgical and aging-related factors may
help explain this observation but results in literature are not concord, especially due to the fact that most data
derive from retrospective studies in which selection bias cannot be excluded. Subsequently, further studies are
necessary to clarify the incidence of acute myocardial infarction in old people.
Background
Benign prostatic hyperplasia (BPH) is a frequent problem
among elderly, and is responsible for significant disability.
BPH is a histological diagnosis that refers to the prolif-
eration of smooth muscle and epithelial cells within the
prostatic transition zone. The prevalence and incidence
of BPH increases with aging. Histologic BPH is present
in around 8% of men aged 31 to 40, 50% of men aged 51
to 60, 70% of men aged 61 to 70, and 90% of men aged
81 to 90. Thereby, symptomatic (clinical) BPH is present
in approximately 26% of men in the fifth decade of life,
33% of men in the sixth decade, 41% of men in the
seventh decade, and 46% of men in the eighth decade of
life and beyond. BPH can be clinically relevant due to
lower urinary tract symptoms (LUTS) that take place
because the gland is enlarged and obstructs urine flow.
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Urinary symptoms can include: a frequent, urgent need
to urinate, difficulty starting urination, slow (prolonged)
urination, nicturia, urinary tract infections, hydronephro-
sis [1]. The enlarged gland seems to contribute to LUTS
via at least two mechanisms: 1) direct bladder outlet
obstruction from enlarged tissue (static component) and
2) increased smooth muscle tone and resistance within
the enlarged gland (dynamic component). Instruments
such as the American Urological Association-Symptom
Index are now widely utilized to quantify the severity of
LUTS in both clinical trials and clinical practice.
The impact of LUTS/BPH on quality of life is very con-
siderable and should not be underestimated [2]. The most
important motivations for treatment is symptoms’ severity
influence on quality life and so the main goal of treatment
is to resolve and alleviate storage and voiding symptoms.
Hence, treatment has been focused on the amelioration of
disease progression and prevention of complications.
A variety of pharmacologic classes are used in medical
treatment including alpha-adrenergic antagonists (alpha-
blockers), 5-alpha-reductase inhibitors, anticholinergics
and phytotherapeutics.
The classic surgical interventions include open prosta-
tectomy (OP) and transurethral resection of prostate
(TURP). OP is an invasive surgical procedure that is indi-
cated for men whose prostates, in the point of view of
the urologist, are too large for TURP for fear of incom-
plete resection, significant bleeding or the risk of hypona-
tremia. TURP remains the gold standard treatment for
patients with moderate or severe LUTS who need active
treatment or who either fail or do not want medical ther-
apy. TURP was developed during the 1930s as a less inva-
sive alternative to OP in the treatment of benign prostatic
enlargement [3]. With increasing worldwide attention on
health care costs, minimally invasive therapies for the
management of BPH (as Transurethral needle ablation,
Transurethral microwave therapy - TUMT, Transure-
thral incision of the prostate, holmium laser enucleation
of the prostate, laser photovaporization of the prostate)
will become progressively more important in cost-
effectiveness evaluations.
However, in the absence of strong evidence favouring
newer technologies, TURP currently remains clinically and
cost effective. Moreover, TURP peri-operative and post-
operative complications still occur. Post-operative compli-
cations of TURP are retrograde ejaculation (60-90% after
TURP), urinary tract infections (cause by bacterial coloni-
zation of the prostate; occurs in 2%), persistent urinary
retention (2.5% went home from the hospital with cathe-
ter), bladder neck stricture (occurs 2-10%), urethral stric-
ture (around 10%; limiting the time of the transurethral
catheter), cardiac complications (acute myocardial infarc-
tion - AMI). The incidence of AMI in patients undergoing
TURP is controversial. The first long-term study by
Roos et al. comprised 54.000 patients from Canada,
England and Denmark and showed an increase in mortal-
ity of 40 % after a follow-up period of 2-7 years. The rela-
tive risk of death from AMI was 2.5 in the TURP group.
In addition in this study, TURP was less effective than
OP [4].
However some confounding factors could not be ruled
since the two populations are not comparable due to
the tendency to assign older and less healthy men to
TURP because it is less traumatic. Furthermore those
studies designed retrospectively did not distinguish pos-
sible prognostic factors which were partially responsible
for the assignment of the patients to TURP or OP. On
the other side, in a study by Shalev at al. there were no
differences in the long-term incidence of AMI after
open or transurethral prostatectomy. Indeed, AMI
developed in the first 3 years after operation in 6.3%
TURP patients compared to 6.9% OP patients. Never-
thless, in men with BPH after both surgical procedures
the incidence of long-term AMI seems to be higher
than in the general male population of the same age
group [5]. Hahn et al. reported a long-term incidence of
AMI of 7.9% after TURP and of 5.2% after TUMT. As
the incidence of AMI in both study arms was higher
than in the general population (standard morbidity
ratio: 1.5), the authors proposed that BPH rather than
the treatment itself is associated with cardiovascular dis-
ease. The similarity of the results for TURP and TUMT
prompts that the prostatic enlargement rather than the
treatment is associated with cardiovascular disease [6].
Another study also confirmed a similar mortality or
incidences of AMI in TURP group compared to OP at
all timepoints (1, 5 and 8 years). Is important to remem-
ber the retrospective nature of this analysis and that
although age of both groups was identical, the comor-
bidity rate was slightly (25.2% vs. 21.2%) higher in the
TURP-group [7]. AMI remains the principal cause of
hospitalizations as well as the leading cause of death
worldwide. In patients with AMI who are older than
70 years, mortality rates exceed 30% [8]. The incidence
and prevalence of MI increase progressively with age. In
the United States, over 60% of AMI occur in patients
65 years of age or older, and approximately one third
occur in persons over age 75 [9].
Coronary heart disease is more advanced in the elderly
than in younger patients. Three-vessel disease occurred
in 44% of subjects with ischemic heart disease aged
65-74 and in 63% of subjects aged 75 and over [10,11].
Heart failure is common in the elderly population.
Approximately 6 to 10 percent of the population 65 years
or older have heart failure. In patients older than 67 years,
median survival is generally less than 3 years after hospita-
lization for heart failure [12,13]. Heart failure is the most
common reason for hospitalization in elderly patients.
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Etiology of heart failure is often multifactorial in the
elderly [14-16]. The common causes of heart failure
include ischemic heart disease, valvular heart disease,
hypertensive heart disease, and cardiomyopathy. The com-
plexity in the presentation and in the evolution of heart
failure in the elderly leads to research new treatments that
can improve the survival of patients with this debilitating
disease [17,18].
Given the conflicting results of the studies in the lit-
erature on AMI incidence in patients undergoing TURP
or OP, in this review we are going to discuss the factors
that may influence the risk of AMI in elderly patients
undergoing prostate surgery. We therefore decided to
analyze the possible common factors that lead to the
development of AMI and BPH (cardiovascular and
metabolic), the stressor factors related to prostatectomy
(surgical and haemodynamic risk factors) and the risk
factors specific of the elderly population (comorbidity
and therapies).
Discussion
Cardiovascular and metabolic factors
Some evidence indicates that the same risk factors asso-
ciated with heart disease may increase the risk of devel-
oping BPH. These risk factors include obesity, diabetes,
diet, dyslipidemia, hypertension [19].
Obesity strikingly increases the risk of BPH. The risk of
BPH increases by 10% for each 0.05-increase in the
waist-to-hip ratio. Increased adiposity is positively related
with radiographically determined prostate volume and
enlargement, suggesting that obesity promotes prostate
growth and rises the risk of clinical BPH and LUTS [20].
Abdominal obesity increases the estrogen-to-androgen
ratio and may lead sympathetic overactivity, both
hypothesized to influence the development of BPH and
the severity of urinary obstructive symptoms. The
increase in adipose aromatization of testosterone to
estrogen and the altered levels of testosterone and sex
hormone binding globulin in patients with raised adipose
stores promote prostatic epithelial and stromal prolifera-
tion. Several mechanisms have been proposed to explain
the relationship between obesity and increased sympa-
thetic tone. Inflammation with elevated serum concentra-
tions of IL-6 and TNF-a, increased insulin levels in
proportion to the amount of adipose stores and leptin
increase have been shown to result in sympathetic overd-
rive. Furthermore activation of the renin- angiotensin-
aldosterone system and adrenal alfa2-adrenergic downre-
gulation and desentitation may enhance sympathetic
tone [21-25].
Diabetes may also significantly influence the risk of
BPH and LUTS in older men. During insulin-resistance,
hyperinsulinemia develops to conuteract the decreased
responsiveness of the body to insulin. Although the
compensatory hyperinsulinemia prevents development
of fasting hyperglycemia in insulin-resistant individuals,
the increased level of circulating insulin directly and/or
indirectly affects different molecular signaling and can
promote prostatic growth. Hyperinsulinemia stimulates
the liver to produce more insulin-like growth factor
(IGF), another mitogen and an anti-apoptotic agent
which binds insulin receptor/IGF receptor and stimu-
lates prostate growth. The levels of IGFs and IGF bind-
ing proteins in prostate tissue and in blood are
associated with BPH risk [26,27]. It has been demon-
strated that a healthy lifestyle plays a critical role in car-
diovascular health. It is now apparent that the same is
true in the development of BPH. Men with high energy
intakes and high intake of protein and polyunsaturated
fatty acid were at greater risk of developing BPH [28].
Daily aerobic exercise can ameliorate methabolism, par-
ticularly when combined with a low-fat, high-fiber diet
consisting of whole grains, fruits, and vegetables. In cell
culture studies, this type of lifestyle regimen has recently
been shown to reduce the growth of serum-stimulated
prostate epithelial cells and the growth of androgen-
dependent prostate cancer cell lines. Alcohol consump-
tion is associated with a decreased likelihood of BPH
but not of LUTS. The association is thought to be
related to alcohol’s cardiovascular effects and modula-
tion of steroid hormone metabolism [29]. The prostate
synthesizes and stores large amounts of cholesterol and
prostate tissues may be particularly sensitive to modifi-
cations in cholesterol metabolism. Hypercholesterolemia,
a major risk factor for cardiovascular disease, is also a
risk factor for BPH. Experimental and clinical findings
indicate that agents that inhibit cholesterol absorption
from the intestine can reduce prostate gland size and
improve LUTS [30].
A considerable, age independent association exists
between BPH symptoms and hypertension. This finding
indicates in increased sympathetic activity a common
pathophysiological factor for both disease states [31].
Elderly patients with nicturia had a higher blood pres-
sure and higher serum catecholamine levels compared
to healthy elderly controls. Furthermore, hypertension
itself seems to have an adverse influence on LUTS and
currently used alfa1-adrenergic receptor antagonists (all
except tamsulosin), were originally developed as antihy-
pertensive drugs.
Surgical risk factors
An important stressful factor to the heart during TURP
procedure is the fluid excess due to absorption of fluid
that enters the circulation via blood vessels in the resec-
tion area. Small amounts are probably of little conse-
quence, but the accidental transfer of > 3 L of fluid results
in symptoms originating from the cardiovascular system
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as well as bradycardia and hypotension and sometimes
involving the central nervous system with neurologic dis-
turbance as confusion, aggressiveness and depressed
consciousness.
The fully developed ‘TURP syndrome’ is a very rare
systemic complication, caused by excessive absorption of
electrolyte-free irrigation fluids but mild forms are quite
common. The incidence of ‘TURP syndrome’ has
decreased significantly during the last few decades from
3% to <1% but this complication is very dangerous
because characterised by symptoms changing from an
asymptomatic hyponatremic state to convulsions, coma
and death.
Symptoms may occur if the amount of fluid absorbed
exceeds 1 litre, which occurs in between 5 and 10% of
the TURPs performed [32]. Normal saline cannot be
used as irrigation solution with conventional monopolar
resection. Glycine solution is generally used as an irriga-
tion solution in traditional therapeutic endoscopic uro-
logic procedures [33].
The role of irrigation solution is to distend the blad-
der, clear the surgical site and wash away residual tissue
and blood. Various irrigation fluids (glycine, sorbitol,
mannitol and normal saline) have been used for TURP.
Glycine solution is the most commonly used irrigant in
traditional therapeutic endoscopic urologic procedures.
To measure serum electrolytes (sodium and potassium
levels) changes during TURP surgery is a simple and eco-
nomical method for indirect assessment of fluid absorp-
tion for early identification of TURP syndrome [34].
Several reports showed that glycine absorption causes
neurologic symptoms and echocardiogram changes, as
well as T-wave depression or inversion on electrocardio-
graphy for up to 24 hours after surgery. Other ECG
alterations due to 1.5 glycine absorption are prolongation
of the RR interval and QRS duration.
Another significant surgical risk factor during TURP is
bleeding and erythrocyte transfusions may subsequently
be necessary. Considerable perioperative bleeding will
impair the visibility of the surgical field, reduce the tis-
sue elimination and raise hypovolemia risk. Hemor-
rhages are one of the major intraoperative complications
with 1 litre or more blood loss in 14% of patients
[35,36].
Transfusion rate decreased in last ten years from 22%
to 0.4-7.1%. Technological improvements of monopolar
and bipolar TURP, microprocessor-controlled units and
better instrumentarium resulted in a significant decrease
of transfusion rates. Some authors have emphasized the
decreased amounts of intra- and postoperative bleeding
when the bipolar device is used. The bipolar electrosur-
gical equipment simultaneously vaporizes the tissue and
controls the bleeding. Because TURP syndrome and
blood loss are strictly related, Huang et al., showed that
bipolar TURP resulted in deeper coagulation zones, less
bleeding, less intraoperative hemoglobin drop, smaller
serum sodium decrease, and therefore no TURP syn-
drome occurred [37]. Important bleeding during surgery
can be also almost eliminated with alternative energy
sources such as the Holmium laser or Potassium Titanyl
Phosphate laser.
Hemodynamic factors
Besides the above mentioned data on TURP and its cor-
relation with AMI incidence, hemodynamic factors have
been suggested as potential triggers of myocardial ische-
mia during TURP. In particular, it has been reported that
body temperature lowering due to cold irrigating fluid
may result in “cardiac stress” as demonstrated by
increased peripheral resistance and arterial pressure, as
well as reduced stroke volume and cardiac output after
TURP compared to control procedures [38]. Other stu-
dies, however, have demonstrated that patients subjected
to OP and TURP presented the same degree of hemody-
namic alterations, without significant differences, imply-
ing that the kind of surgery does not play a relevant role
in the late mortality rate of these patients [39]. Further
evidence on the hypothesis of TURP-related cardiac
stress come from studies evaluating cardiac enzyme levels
after this surgical procedure. A slight increases in creati-
nine kinase-B subunit and lactate dehydrogenase 1 has
been reported in patients undergoing TURP, but the cri-
teria for AMI were never fulfilled [40]. More recently, it
has been shown that Troponin T is not increased in
patients undergoing TURP without previous cardiac pro-
blems. Pro-brain natriuretic peptide is modestly
increased but it does not indicate significant ventricular
dysfunction [41,42].
Thus, the clinical significance of these increases
remains unknown and it is likely that patients with a
history of cardiac disease are at a higher risk of myocar-
dial damage during TURP. On the other hand, in elderly
patients with no history of heart disease undergoing
TURP, continuous ECG Holter monitoring during the
pre- intra- and post-operative periods was not able to
detect significant variations in electrocardiographical
signs indicative for ischemic disease [43].
Comorbidities and therapies
It is well established that benign prostatic hyperplasia is
associated with old age and both OP and TURP are per-
formed in patients with multiple comorbidities. The
study by Roos et al. was the first to compare long-term
mortality after TURP to OP, showing that TURP resulted
in higher long-term mortality compared to OP [4]. How-
ever, this study, as mentioned above, was retrospective
and confounding factors leading to altered patients’ selec-
tion could not be ruled. In fact, given the less invasive
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nature of TURP compared to OP, it is likely that patients
with multiple comorbidities and higher surgical risk are
preferentially referred to TURP, leading to a selection
bias that cannot be eliminated in retrospective studies.
Moreover, although some studies have confirmed a direct
effect of comorbidity on perioperative morbidity and
mortality after these procedures [44-46].
Recent evidence indicate that both interventions result
in similar cardiovascular outcome. Madersbacher et al.
have shown that despite the fact that comorbidity rate
was slightly higher in patients undergoing TURP com-
pared to OP, no excess risk of AMI or death after
TURP were observed [7]. However, in studies comparing
TURP to other mini-invasive techniques, such as
TUMT, it has been shown that both interventions are
followed by a higher incidence of AMI compared to the
general population in patients suffering from various
comorbidities (asthma, cardiovascular disease, diabetes)
[6]. A recent study specifically evaluated the effect of
comorbidities on outcome after TURP and OP indicat-
ing that, despite the high prevalence of comorbid condi-
tions in this population, no comorbidity taken alone can
be considered an absolute contraindication for these
procedures and is associated with the occurrence of
complications [47].
Another specific feature of the elderly population is the
polypharmacotherapy, that is strictly related to increased
comorbidity. Anticoagulant and antiplatelet drugs are
widely prescribed in elderly patients, especially those
with increased cardiovascular risk. Some studies have
evaluated how the management of these drugs can affect
outcome in patients undergoing TURP, since stopping
anticoagulants prior to TURP may reduce peri-operative
blood loss, but it may also increase the risk of cardiovas-
cular events. A recent survey conducted in the United
Kingdom has shown that there is a wide variation in
stopping aspirin before TURP among urologists [48]. In
particular, aspirin is stopped also in patients with
increased cardiovascular risk factors, exposing them to
the risk of complications. However, a retrospective analy-
sis has indicated that men who have anticoagulation ther-
apy stopped before TURP do not have a higher incidence
of cardiovascular, cerebrovascular or thromboembolic
events, or bleedings when compared with anticoagulant-
naïve patients [49,50]. It has also been reported that in
patients undergoing TURP a hypercoagulable state can
be detected and that surgery itself increases the risk of
thrombogenic events [51], thus it is not safe to leave
high-risk patients without effective anticoagulation, but
to address this issue further studies are needed.
As for lifestyle habits and non-pharmacological inter-
ventions, some studies have shown that physical activity
may have a protective role on prostatic hyperplasia
[52-54]. In particular, it has been observed that an
inverse relationship exists between physical activity and
prostatic hyperplasia with a risk reduction for both
incident surgery and symptomatic cases among non-
sedentary men [55-58]. It has been hypothesized that
reduction in sympathetic nervous system activity result-
ing from regular physical training is also able to reduce
prostatic smooth muscle tone. In fact, it is well estab-
lished that aging is associated with altered sympathetic
tone and that exercise training has beneficial effects on
cardiovascular risk profile in the elderly.
Summary
Although urological surgery - and TURP in particular - is
considered at low risk for subsequent severe complica-
tions, there are several reports indicating that cardiovas-
cular events in elderly patients undergoing these
procedures are more common than in the general popu-
lation. Several cardio-metabolic, surgical and aging-
related factors may help explain this observation but the
picture still remains confusing, especially due to the fact
that most data derive from retrospective studies in which
selection bias cannot be excluded. Moreover, recent
guidelines suggest to consider patients aged more than
60 years with no history of cardiopulmonary disease at
intermediate surgical risk, indicating that age per se plays
a role in surgery-specific risk [59].
Thus, the efforts to reduce cardiovascular complica-
tions in elderly patients should continue, focusing on
better stratification of the risk of atherosclerotic coron-
ary artery disease, detection of the presence of ischemia,
and management of surgery-related cardiovascular stres-
sors. In this vein, prospective studies might help clarify
unsolved clinical issues and identify pathophysiological
mechanisms underlying increased cardiovascular risk in
urological elderly patients.
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